Haemonetics Corporation (NYSE:HAE) is looking for acquisitions. During the company?s fourth quarter of 2024 earnings conference call, James D'Arecca, Chief Financial Officer said that ?With our new credit agreement and our ability to generate strong EBITDA and free cash flow, we estimate our available capital capacity to be in excess of $1 billion by the end of fiscal '25 and up to about $2 billion by the end of fiscal '26, after nearly $500 million of capital we have already allocated to M&A and share buybacks since we issued our long-range plan in June of 2022. We plan to continue to leverage our access to capital to further expand our product portfolio and lay the foundation for additional growth, including additional strategic tuck-in acquisitions for our interventional technologies portfolio in the near term?.

Christopher Simon, Chief Executive Officer said that ?We do see other opportunities for tuck-in acquisitions in the interventional technology franchise. And so we will action those as the market opportunity presents itself. We wanted to have that capacity on the balance sheet to be able to do that.

But we really see those as tuck-ins and things that would be highly accretive to growth and profitability as we roll forward?.